Katherine Hasal

Treatment with fixed-dos combination sofosbuvir/velpatasvir yielded significant improvements in patient-reported outcomes.

Filgotinib is the first oral, JAK1-selective inhibitor showing efficacy in moderate-to-severe Crohn's disease patients.

Risankizumab is a humanized monoclonal antibody that selectively inhibits IL-23 through specific targeting of the IL-23 p19 subunit.

Researchers reported that SVR12 rates in real-world, post-transplant genotype 1 HCV patients treated with ledipasvir-sofosbuvir, with or without ribavirin, is 98% across regimens and various characteristics.

Researchers report promising results from the QUARTZ-I study that assessed the efficacy of the 3D regimen combined with sofosbuvir in treatment-experienced patients with HCV genotype 1 infection.

Results from the ION-3 trial showed that the rapidity and durability of viral suppression achieved with ledipasvir-sofosbuvir therapy allows a shorter treatment course of 8 weeks in genotype 1, treatment-naïve, non-cirrhotic patients.

The new Rome IV criteria classify the functional bowel disorders into five distinct categories, including irritable bowel syndrome (IBS), functional constipation, functional diarrhea, functional abdominal bloating/distention, and unspecified functional bowel disorder. A new category for opioid-induced constipation, which is distinct from the functional bowel disorders, has been added.

Rome IV updates include more specific definitions and diagnostic criteria for functional gastroduodenal disorders such as functional dyspepsia, belching disorders, and nausea and vomiting disorders.

The Rome Foundation announced the release of updated and revised Rome IV diagnostic criteria for more than 20 different gastrointestinal disorders at DDW 2016.

Although there was widespread circulation of influenza viruses that were antigenically drifted from the vaccine virus, last year's flu vaccine appears to have been effective in preventing severe illness requiring hospitalization.

Researchers have identified GS-5734 (a prodrug of adenine nucleotide analog) as an inhibitor of pathogenic filoviruses, such as the Ebola virus.

Test performs comparably to standard reverse-transcriptase polymerase chain reaction assays using whole blood and buccal swab specimens.

Study results show there are minimal drug-drug interactions between tenofovir alafenamide-based antiretroviral regimens for HIV and ledipasvir/sofosbuvir combination treatment for hepatitis C.

Treatment simplification maintains viral suppression and reduces proteinuria, potentially improving treatment adherence.

Treatment-experienced patients with HIV who switched to a tenofovir alafenamide-based treatment regimen maintained excellent virologic suppression while exhibiting significant improvements in both bone and renal safety.

Patients on non-recommended treatment regimens are less likely to achieve viral suppression and more likely to report side effects.

Researchers report that waiting more than 2 years between HIV screenings is associated with double the rate of AIDS by CD4+ criteria at the time of HIV diagnosis when compared with more frequent testing.

The new guidelines provide important updates in four key areas, including behavioral screening for possible HIV transmission, sexually transmitted disease screening and treatment, HIV partner services, and referral for medical and social services.

Ability to differentiate between subtypes of frontotemporal lobar degeneration could accelerate research into the pathology and prevention of this disease and aid in the design of disease-modifying therapies.

Study results suggest that oxidative stress may play a direct role in the neurodegeneration that occurs in ALS.

DaTscanâ„¢ SPECT imaging can help physicians assess diagnostic category and improve diagnostic confidence for patients with dementia with Lewy bodies.

Patients with Parkinson's disease and neurogenic orthostatic hypotension treated with droxidopa showed improvements in symptoms of dizziness and lightheadedness, and in systolic blood pressure.

Researchers report the monoclonal antibody solanezumab may improve cognition and activities of daily living for patients with mild Alzheimer's disease.

Study shows levetiracetam, carbamazepine, and topiramate are equally safe and effective in the treatment of adult patients with epilepsy induced by MELAS. However, valproate was found to be less effective and associated with more adverse events.

Researchers successfully treated a patient with refractory complex regional pain syndrome by inducing a coma with ketamine and dexmedetomidine.

Study results show that intrathecal ziconotide provides significant pain relief for patients with refractory painful myelopathies and neuropathies.

Study results show that IPX066 demonstrated a favorable tolerability profile throughout extended dosing in early Parkinson's disease (PD) and during the long-term management of patients with advanced PD.

In the MOTION and SETTLE studies, safinamide was shown to be effective in the treatment of patients with Parkinson's disease as add-on therapy to a stable dose of a single dopamine agonist and as add-on therapy for patients taking levodopa.

Switching from oral administration of the non-ergoline dopamine agonist, rotigotine, to a transdermal delivery system may improve gastrointestinal symptoms for patients with Parkinson's disease.